Monday 5 August 2019

Smart Biosensors Market to show steady growth, 2019

Market Scenario:
Biosensors are analytical devices used for detection of chemical and biological substances in the human body. Smart biosensors are easy to use, simple, accurate and effective than traditional methods of analysis. Biosensors are becoming popular in developed countries. The increasing prevalence of diabetes in emerging economies, demand for advanced monitoring systems, and increasing awareness about advance biosensors are expected to drive the growth of the market. According to the report published by World Health Organization(WHO) in 2016, diabetes is a major healthcare concern in Brazil, and it affected more than 8.1% of the population, the prevalence of diabetes was more in females, and it affected more than 8.8% females in the country. Moreover, rising R&D spending and collaborative strategies adopted by the top players such as new product launches and collaborations for product development are contributing to the growth of the market.
The Global Smart Biosensors Market accounted for USD 12000 million and expected to register 7.64% CAGR during the forecast period (2018–2023)
The rising cost of biosensors and unfavorable reimbursement policies may hamper the growth of the market during the assessment period.
Top Key Players
  • Abbott Point of Care Inc.,
  • Medtronic Inc.,
  • Hoffman La-Roche Ltd.,
  • Siemens Healthcare AG,
  • Lifescan, Inc.,
  • LifeSensors Inc.,
  • Nova Biomedical Corp.,
  • Acon Laboratories Inc.,
  • Universal Biosensors,
  • Pharmaco-Kinesis Corporation,
Segmentation
The global smart biosensors market has been segmented on the basis of product type, technology, application, and end user.
On the basis of product type, the market has been classified as wearable biosensors, non-wearable biosensors.
The technology segment has been divided into electrochemical biosensors, piezoelectric biosensors, optical biosensors, thermal biosensors, nanomechanical biosensors, and others. thermal biosensors segment is likely to be the fastest growing segment during the forecast period.
The market, by application, has been segmented into blood glucose testing, cholesterol testing, blood gas analysis, pregnancy testing, drug discovery, infectious disease testing, and others.
The end user segment has been divided into point-of-care, home diagnostics, research labs, security & biodefense, environmental monitoring, food & beverage industry, and others
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The smart biosensors market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European smart biosensors market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The smart biosensors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The smart biosensors market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas are expected to hold the maximum share of global smart biosensors market owing to the rising prevalence of chronic disorders, favorable policies implemented by government and regulatory authorities, and adoption of highly advanced technology. According to the article published in 2016 by National Council on Aging, the prevalence of Chronic disorders in American regions is continuously increasing and about 80 percent of older adults have at least one chronic disease, and more than 68 percent were suffering from more than one chronic disorders.
The European market is likely to be the second-largest smart biosensors market. The market growth in this region can be attributed to the presence of well-established healthcare system in the region, government initiatives for controlling chronic disorders, and increase in the population suffering from cardiovascular disorders. According to the European Heart Network, cardiovascular disorders are responsible for 3.9 million deaths in the European Union which are 45% of the total deaths.
Asia-Pacific is expected to be the fastest-growing smart biosensors market during the forecast period owing to the increasing prevalence of diabetes, increasing disposable income, and government initiatives for the development of the healthcare sector. According to the International Diabetes Federation, in 2017, more than 84 million people in South-East Asia were affected by diabetes, and this number is expected to reach 156 million by 2045.
The market in the Middle East & Africa is expected to hold the smallest share of the global smart biosensors market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures at @ https://www.marketresearchfuture.com/reports/smart-biosensors-market-7801

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Anti-Hypertensive Drugs Market in depth study and analysis published, 2019

This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global Anti-Hypertensive Drugs Market over the forecast period. 
According to a recent study report published by the Market Research Future, The global market of  Anti-Hypertensive Drugs was valued at $32.2 billion in 2015, and is projected to reach $ USD 41.2 billion by 2023. Thus the market is anticipated to observe a sluggish growth; at a CAGR of 2.73% during 2016 to 2022.
Anti-Hypertensive Drugs are used to treat hypertension (high blood pressure). Hypertension is a state of chronic elevated arterial blood pressure at or greater than 140/90 mm Hg for adults. Hypertension is one of the most powerful risk factors for cardiovascular morbidity and mortality. There exact cause of hypertension is unknown but is said that unhealthy, heady lifestyle and ageing mirror such disorders as “Hypertension”.
The major market driving factors for secondary hypertension are greater detection and early diagnosis. Rise in the prevalence diseases such as kidney problems, thyroid problems, adrenal gland tumours, heart ailments, chronic alcohol use etc. in which anti-hypertensive drugs are used; are some of the other factors driving the growth of the Anti-Hypertensive Drugs market. The constraints however are overwhelming and include patent expiries such as Actelion's Tracleer (2015), and United Therapeutic's Remodulin (2014). Other blockbuster’s such as Novartis's Diovan and Exforge, Sanofi Aventis's Avapro (2012) etc are also off-patent.
Many antihypertensive drugs have their primary action on systemic vascular resistance. Some of these drugs produce vasodilation by interfering with sympathetic adrenergic vascular tone (sympatholytics) or by blocking the formation of angiotensin II or its vascular receptors. Other drugs are direct arterial dilators, and some are mixed arterial and venous dilators. Although less commonly used because of a high incidence of side effects, there are drugs that act on regions in the brain that control sympathetic autonomic outflow. By reducing sympathetic efferent activity, centrally acting drugs decrease arterial pressure by decreasing systemic vascular resistance and cardiac output.
Some antihypertensive drugs, most notably beta-blockers, depress heart rate and contractility (this decreases stroke volume) by blocking the influence of sympathetic nerves on the heart. Calcium-channel blockers, especially those that are more cardioselective, also reduce cardiac output by decreasing heart rate and contractility. Some calcium-channel blockers (most notably the dihydropyridines) are more selective for the systemic vasculature and therefore reduce systemic vascular resistance.
Competitive Analysis
  • United Therapeutics Corporation (U.S.)
  • AstraZeneca (U.K.)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (U.S.)
  • Daiichi Sankyo Company, Ltd. (Japan)
  • Boehringer Engelheim GmbH (Germany)
  • Johnson & Johnson Services, Inc. (U.S.)
  • Takeda Pharmaceutical Company (Japan)
  • Sanofi S.A. (France)
  • Merck KGaA (Germany)
  • Bayer AG (Germany)
Segmentation
The Anti-Hypertensive Market can be segmented in to 4 key dynamics for the convenience of the report and enhanced understanding;
Segmentation By Pharmacological Class          : Comprises Diuretics, ACE Inhibitors, Calcium Channel Blockers, Adrenergic Blocker and other.
Segmentation By Hypertension Type               : Comprises Systemic and Pulmonary Hypertension Drugs and other.
Segmentation By Disease Source                    : Comprises Primary and Secondary.
Segmentation By Regions                               : Comprises Geographical regions - North America, Europe, APAC and Rest of the World.
Regional Analysis
The antihypertensive drugs market covers growth drivers in the following regions, namely Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). The Americas accounted for a large market share owing to high prevalence of hypertension linked to cardiovascular and renal disorders. Drives by government and non-government organizations for creating awareness of the medical condition are likely to bolster the revenue of the antihypertensive drugs market in Americas.
The Europe region was the second-largest due to rise of cardiovascular diseases, unhealthy diets, and increase noticed in obesity levels of patients. According to the European Heart Network in 2017, heart diseases accounted for 3.9 million deaths. Germany, France, and the U.K. are expected to be the prime contributors to the antihypertensive drugs market in Europe.
The APAC region is projected to exhibit a robust pace owing to increased healthcare budget and rise in disposable income levels of patients. The setup of research and development centers to fast-track the commoditization of drugs for treating hypertension is likely to boost the APAC antihypertensive drugs market.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @  https://www.marketresearchfuture.com/reports/anti-hypertensive-drugs-market-2347

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Thursday 1 August 2019

Global Genetic Testing Market Recent Trends, Growth Opportunities, Forecast by Application and Types to 2023

The Global Genetic Testing Market is expected to grow at CAGR of 11.50% to reach USD 22834.19 million till 2024. Some of the protuberant drivers supporting the growth of the global genetic testing market are identified as raising awareness about the benefits of genetic testing and the rising prevalence of genetic disorders.
Additionally, the role of genetic tests in forensic investigations and change in the trend of the genetic testing industry from service-driven to product-driven industry are expected to drive the global genetic testing market in the coming years.
Genetic testing is also known as DNA testing. Genetic tests involve a set of lab tests for the study of the genetic makeup of patients and identify any gene mutations and alterations in the healthy structure of DNA leading to the development of genetic disorders. Genetic testing offers a lot of benefits such as the chance for taking preventive measures to avoid potential diseases and lead a healthy life, knowledge about genetic alterations in the fetus that may lead to abnormal growth, and aids forensic investigations, among others. Due to the great benefits provided by these tests, people are getting more aware of them. This phenomenon intrigues people to go for tests to understand their genetic structure and possible disorders they may have to go through. The growing awareness has gathered a lot of audience for the genetic testing market and has also positively impacted the growth of this market.
Moreover, there has been tremendous growth in the prevalence of genetic disorders which may be due to various reasons such as geographical and environmental changes, change in food habits, pollution, and exposure to harmful radiations or chemicals. Genetic tests are also used to analyze family relations such as father, mother, half-brother, half-sister, and others. Forensic science and genetic testing have aided law and order to a great extent. With an increasing number of companies entering into this segment, the overall market for genetic tests has increased and expected to grow fast in the near future.
Key Players
The prominent players in the global genetic testing market are Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), Illumina Inc. (US), Myriad Genetics, Inc. (US), PerkinElmer Inc. (US), QIAGEN N. V.  (Germany), Quest Diagnostics Incorporated (US), Eurofins Scientific (US), F. Hoffmann-La Roche Ltd (Switzerland), Blueprint Genetics (Finland), BGI Genomics (China), and Thermo Fisher Scientific Inc. (US).
Some of the key strategies followed by the players operating in the global genetic testing market were innovation, product development, acquisition, and expansion.
  • In April 2017, Myriad Genetics, Inc. signed an agreement with Clovis Oncology for the use of its FDA-Approved BRACAnalysis CDx Test to identify patients with germline BRCA Mutations for the Rubraca (rucaparib) treatment.
  • In January 2017, Bio-Rad Laboratories, Inc. announced the launch of the Single Cell Sequencing Solution in collaboration with Illumina Inc.
  • In August 2016, Abbott Laboratories launched Alinity, a family of next-generation system.
Segmentation                                                                                                                                        
Global genetic testing Market, by type, segmented into prescribed genetic testing and direct to consumer genetic testing. Prescribed genetic testing is the leading segment, which is growing at the highest CAGR to reach USD 21653.91 million by the end of 2024. Its large market share is majorly attributed to the widespread availability and service providers of various genetic tests and less availability of direct to consumer tests in all parts of the world.
Based on method, the genetic testing market is segmented into molecular genetic tests/ DNA tests, chromosomal genetic tests, and biochemical genetic tests. The molecular genetic test/DNA tests account for major share with 11.78% CAGR during the forecast period. Molecular testing helps to determine the sequence in DNA or RNA related to a particular disease.
The genetic testing market, by application, is segmented into reproductive health, cancer screening, ancestry, predictive and pre-symptomatic testing, and others. The reproductive health segment accounted for the largest market share of 33.61% in 2018.
Regional Analysis         
The Americas accounted for the largest market share of the global genetic testing market, by region in 2018. This large share is majorly due to high awareness about genetic testing, high disposable income of the population, and implementation of newborn screening in the majority of the hospitals in the region. In 2015, approximately 12 million Americans suffered from genetic diseases which are approximately 1 in 20 people.
Europe accounted for the second largest market share. Technological advances, well-developed health care sector, and governmental support for the research and development of different tests and devices have provided fuel for the growth of the market. Germany commands the largest market share in the Europe genetic testing market.
Asia-Pacific is the fastest growing region for genetic testing. The presence of a huge patient population, rapid development in technology, and the presence of huge opportunities for the development of the market drive the growth of the Asia-Pacific genetic testing market. The Middle East & Africa accounted for the 8.8% market share in 2018.
Browse Complete 140 Pages Premium Research Report Enabled with 174 Respective Tables and Figures at @ https://www.marketresearchfuture.com/reports/genetic-testing-market-2009

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Microbiology Testing Market to Observe Significant Growth by 2019

Market Scenario
The Global Microbiology Testing Market is expecting a more than twofold rise from USD 2706.1 million in 2016 to USD 5409.1 million by 2023, reports Market Research Future (MRFR). The extensively studied report covers the drivers that are going to impact the market decidedly during the forecast period (2014-2023) and delivers a much-precise predictive analysis of the coming years of the market. Infectious diseases are on the rise, and several outbreaks of epidemics across the globe have spurred the demand for microbiology testing. Healthcare segment is witnessing a significant increase in expenditure all over the world, and an increase in research allotments are a positive sign for the microbiology testing market.
Microbiology testing has emerged as one of the rapidly changing segment of healthcare over the past few years. Microbiology testing deals with the study of microbial germs and their clinical applications for the improvement of health. Increasing prevalence of various infectious diseases are driving the growth for global microbiology testing market.
However, the market can witness a slight pullback caused by stringent regulatory frameworks, and patient reimbursement policies can impede the market growth for a short span of time. But the bottlenecked market can see a wider scope of possibility with improving technologies in the field of product enhancement which can ease the market growth considerably.
The key factor supporting the global microbiology testing market growth is the increasing prevalence of various infectious diseases. The global microbiology testing market has been segmented into application, end user, product type, and lastly, region. The application-based segmentation of this market comprises of gastrointestinal infections, respiratory infections, sexually transmitted infections, urinary tract infections, and others.
Key Players
The key players in the global microbiology testing market include Alere (USA), Beckman Coulter Inc. (USA), Becton Dickinson (BD) (USA), Biomérieux SA (France), Cepheid (USA), F. Hoffmann-La Roche Ltd (Switzerland), and Thermo Fisher Scientific Inc. (USA).
Latest Industry News
  • Leading small molecule innovator and generic Active Pharmaceutical Ingredients (APIs) manufacturer Cambrex Corporation, who also specialize in finished dosage forms, has acquired Avista Pharma Solutions (“Avista”), a contract development, manufacturing, and testing organization, from Ampersand Capital Partners. Avista is also a microbiology testing leader. 2 JAN 2019
  • Clear Safety, the flagship product of Clear Labs has received AOAC Performance Tested certification for Salmonella enterica Clear Labs is a unique automated and intelligent next-generation sequencing (NGS) platform purpose-built for food safety testing. Clear Safety combines advanced microbiology, data science, robotic automation, software analytics, and state-of-the-art NGS sequencing, to not only to lower the costs significantly but to also achieve greater than 99.9% accuracy. 4 DEC 2018
Segments 
Global Microbiology testing Market has been segmented on the basis of type which comprise Instruments, Chemicals & Reagents, Consumables & Accessories, and others. On the basis of application, it is segmented into, Gastrointestinal Infections, Respiratory Infections, Urinary tract Infections, Sexually Transmitted Infections, Others. On the basis of end user, it is segmented into, Hospital based laboratory, Independent laboratory, and Academics & Research Institutes.
Regional Analysis
The regional segmentation of the global microbiology testing market can segment the global market into regional markets by the names of Asia Pacific, North America, Europe, and the Middle East & Africa (MEA). In 2016, North America held the largest share market in the global market which was 37.9%. During the forecast period, North America is expected to continue as the largest regional market because the advanced medical facilities are available in this region and support from government regarding investment on the research & development (R&D) is available. The indispensable country-specific markets in this region are USA and Canada. Many key market players are based in North America, especially in the USA.
In 2016, Europe was the second largest microbiology testing market. During the forecast period, there are expectations regarding steady and positive market growth. However, Europe may not retain its spot by the end of forecast period. European government support R&D investment in the medical sector and in terms of technological advancement in the medical sector, Europe is second only to North America. This makes Europe an important regional market. The most significant country-specific markets in this region are France, Germany, Italy, Spain, and the UK, followed by the remaining countries of Europe.
Right now, Asia Pacific is the second largest and fastest growing market in the global microbiology testing market this is to continue till the end of forecast period. This market is expected to grow at 12.1% CAGR between 2017 and 2023. The priority country-specific markets in this region are Australia, China, India, South Korea, and Japan, followed by the remaining countries of the Asia Pacific region.
The MEA region has the least market share due to poor countries, lack of awareness, lack of education, low standard of medical facilities, lack of advanced technology, lack of healthcare facilities, and majority governments not considering healthcare a priority. In this region, the primary country-specific markets are Egypt, Saudi Arabia, and UAE, followed by the remaining countries of the MEA region.
Browse Complete 129 Pages Premium Research Report Enabled with 129 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/microbiology-testing-market-697

         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Age-Related Macular Degeneration Market - Granular Market Report and Review, 2019

This MRFR study offers a vivid view of the global age-related macular degeneration AMD market. The study includes an in-depth analysis of macro and micro-economic factors likely to influence the market during the forecast period. It further summarizes the key market opportunities and trends.
As per the study offered by Market Research Future (MRFR), the global age related macular degeneration market is set to expand at a CAGR of 8.3% during the forecast period 2018 to 2023. The valuation of the market is predicted to grow from USD 1.37 Bn at the end of 2017 to 2.21 Bn by 2023-end. The growing patient pool of a geriatric population is leading the expansion of the market. It is estimated that AMD contributes significantly towards visual loss among the elderly population. In addition, the global aging population is expected to get doubled by the end of 2020. It is presumed to aid the proliferation of the age related macular degeneration market over the assessment period.
Regionally, the Americas age-related macular degeneration market is segmented into two major regions, namely, North America and South America.
The market is lucrative at present, and the rising awareness about the diseases is further expected to boost the growth trajectory of the age related macular degeneration market in the foreseeable future. On the flip side, unfavorable reimbursement policies and the high cost of drugs remain impediments to the market growth.
The expiry of drug patents for widely accepted branded drugs have opened new avenues of growth opportunities for the market participants. Investments are prognosticated to flow towards the development in the formulas of existing drugs for enhanced efficiency. In addition, expired drug patents have paved the way for a reduction in price points, thus, augmenting the global age related macular degeneration market.
Competitive Dashboard:
  • Regeneron Pharmaceutical Inc.,
  • Rxi Pharmaceuticals,
  • Hoffmann-La Roche AG,
  • Santen Pharmaceuticals
  • Bayer AG,
  • Pfizer Inc.,
  • Allergan,
  • Novartis AG,
  • Bausch & Lomb Incorporated,
  • Alimera Sciences.
Market Segmentation:
By type, the global age related macular degeneration market has been segmented into wet AMD and dry AMD.
By diagnosis & treatment, the age related macular degeneration market has been segmented into treatment and diagnosis.
By route of administration, the global age related macular degeneration market is segmented into intravitreal, intravenous, and others.
By stages, the age related macular degeneration market has been segmented into intermediate AMD, early AMD, and late AMD.
By age group, the global age related macular degeneration market has been segmented into above 75, above 60, and above 40.
By end-user, the age related macular degeneration market has been segmented into hospitals & clinics, diagnostic centers, academic research institutes, and others.
Regional Analysis:
The age related macular degeneration market, by region, has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa. The Americas is projected to hold a dominant share of the global market through the forecast period. The rising burden of the disease in the region is expected to drive the proliferation of the regional market. According to the Centers for Disease Control and Prevention (CDC), 1.8 million people were suffering from the disease in 2015 in the U.S.
Europe is an important growth pocket placed at the second position in the marketplace. It is predicted to benefit from rising geriatric population and increasing healthcare expenditure. Meanwhile, Asia Pacific is likely to emerge as the fastest growing regional market for AMD over the assessment period. The factors that are responsible for favoring the expansion of the age-related macular degeneration market in the region are rising healthcare expenditure, increasing prevalence of eye-disorders, growing geriatric population, etc.
Industry News:
In November 2018, the European Court of Justice has determined that Avastin by Roche can be reimbursed for the treatment of age-related macular degeneration despite the challenge imposed by Bayer and Novartis.
In December 2018, the U.S. based Ophthotech Corp. has scrapped the clinical trials of C5 inhibitor for the treatment of wet age-related macular degeneration in spite of successful phase 2a results exhibiting tolerance for imura (avacincaptad pegol) in combination with ranibizumab (Lucentis).
In December 2018, a team of British scientists has announced that they are piloting an eye drop aimed at treating age-related macular degeneration (AMD). The researchers have concluded successful trials on rabbits and pigs and will be tried on human eyes in 2019.
Browse Complete 220 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/age-related-macular-degeneration-market-5736

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Current and forthcoming Liquid Biopsy Market size in terms of volume and value 2019

Market Insights:
Liquid biopsy overcomes these problems of tissue biopsy by using biomarkers present in samples such as blood, urine etc. and thus is a comparatively non-invasive technique. Liquid biopsy also provides greater information about the sample which is real time. The real time data can be used for monitoring and thereby determining the treatment for diseases such as cancer. The greater sensitivity of tissue biopsy coupled with the development of sophisticated detectors with extremely low detection rates have enabled the early detection of diseases which is the holy grail of cancer.
Biopsy involves extracting a sample of tissue and testing it for the presence of diseases especially cancer. Traditional tissue biopsy is a painful technique and also has a high rate of false results. Moreover the technique is costly, time consuming and not applicable for extracting samples such as those close to vital organs such as heart.
Segmentation:
Global Liquid Biopsy market has been segmented on the basis of biomarker type which comprises of circulating tumor cells (Ctcs), circulating tumor DNA (Ctdna), extracellular vesicles (Evs) and other biomarker. On the basis of application; market is segmented into cancer therapeutic application, reproductive health, and other therapeutic application. On the basis of sample; market is segmented into blood, urine and others. On the basis of end-users; market is segmented into hospitals and laboratories, academic and research centres and others.
Major Players

  • Guardant Health, Inc.,
  • Trovagene, Inc.,
  • RainDance Technologies, Inc.,
  • Agena Bioscience Inc. Inc.,
  • Admera Health,
  • Biocept, Inc.,
  • Circulogene Theranostics,
  • Inivata Ltd.,
  • SAGA Diagnostics AB,
  • Exosome Diagnostics and others.
Drivers
The market drivers for the liquid biopsy market are rising rates of cancer, growing investment in research and development, collaborations between companies and public organizations, rise in geriatric population, rising expenditure on health etc. The factors which are inhibiting the growth of the market includes the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. However, not all cancer patients benefit from early detection as some cancer types such as brain cancer and prostate cancer may lie dormant for many years. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.
Also the technique is not applicable to all types of cancer as some cancers such as brain cancer and prostate cancer may lie dormant for many years, and thus are either undetectable or detected very late which robs liquid biopsy of its advantages. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.
Regional Analysis:
Depending on geographic region, Liquid biopsy market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally developed countries led by North America is the largest market for Liquid biopsy. Europe is the second-largest market for liquid biopsy. The developing regions market such as Asia pacific region and Middle East & Africa however is rising much faster.
Key findings
  • Circulating tumor cells (CTCs) segment dominates both in terms of market share as well as revenues, contributing approx. 55.48% of the revenue share of the liquid biopsy market.
  • On the basis of the therapeutic application, the segment for Cancer will reflect the highest growth potential, with over 82.83% of the market share by revenues. However, the urine sample segment is anticipated to witness noticeable growth.
  • The market for liquid biopsy is dominated by North America and Europe and this trend will continue. Asia-Pacific market is the fastest growing market and is expected to grow at a CAGR of 29.7% during forecasted period
Browse Complete 171 Pages Premium Research Report Enabled with 248 Respective Tables and Figures at @ https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Precision Medicine Market 2019 - Opportunity, Driving Trends and deep study 2022

Market Research Future adds the “Global Precision Medicine Market Research Report – Forecast to 2022” report to their unique collection. The major market driving factor for precision medicine are patient’s involvement in personal healthcare, integration of wireless technologies with portable healthcare devices, and increase in genetic diseases (due to mutation, UV rays) among others.
Precision medicine refers to medicines developed as per an individual’s genetic profile that helps as a guide for the prevention, diagnosis and treatment of diseases. The global precision medicine market was valued at $38.92 billion in 2015, and is expected to reach $88.64 billion by 2022. Thus the market is expected to perform a growth at a CAGR of 12.48% from 2015 to 2022.
The market constraints include potential threat to personal data, high diagnostic cost as a barrier, potential risk of hardware or software failure, stringent regulations and standards, lack of awareness about the possible applications of precision medicine, reimbursement policies and regulatory framework, limited knowledge about the application of test and techniques, lack of research and evidences creating hindrances in its application.
Key Players for Global Precision Medicine Market:
Abbott Laboratories, Almac Group, Ltd., Asuragen, Inc., Biomérieux Sa, Cepheid Inc., Cetics Healthcare Technologies Gmbh, Ge Healthcare, Glaxosmithkline Plc, Johnson & Johnson, Laboratory Corporation Of America Holdings, Medtronic, Novartis, Pfizer Inc., Qiagen, Biobase Gmbh, Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi Pharma, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Ab-Biotics Sa, Caris Life Sciences, Healthcore, Inc., Ibm, Innventis, Intel Corporation, Molecular Health Gmbh, Precision For Medicine
Key Findings:
  • The global precision medicine market is expected to reach USD 88.64 billion by 2022.
  • By ecosystem diagnostic tool companies holds the largest market share of precision medicine market and is expected to reach USD 27.56 billion by 2022.
  • By sub-market, company diagnostics holds the largest market share of precision medicine market and is expected to reach USD 21.32 billion by 2022.
Segmentation:
Global Precision Medicine market has been segmented on the basis of ecosystem, sub-market, therapeutics and region.
Regional Analysis
Globally North America is the largest market for global precision medicine. Europe is the second-largest market for global precision medicine. The near future market for precision medicine will be dominated by the developed regions with developing regions providing a supporting role only. However the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.
Browse Complete 313 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/precision-medicine-market-925

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Posts (Atom)